1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,576 | 1,836 | 13.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MOLECURE Aktie jetzt für 0€ handeln | |||||
| 28.03. | Strategic update on the progress and development of Molecure's key clinical projects in 2024 | 283 | GlobeNewswire (Europe) | Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02.... ► Artikel lesen |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,391 | +1,93 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy | RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted... ► Artikel lesen | |
| IMMATICS | 8,510 | -0,58 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| ALDEYRA | 4,121 | +6,43 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| MEDIFAST | 10,240 | -2,85 % | Medifast's Q3 Loss Wider Than Expected, Sales Decline 36% Y/Y | ||
| PHARMING | 1,499 | +0,27 % | Pharming Group N.V.: Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit | Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,257 | +8,84 % | Positive Studiendaten zu Krebsmedikament beflügeln Aktie von Coherus BioSciences | ||
| ORUKA THERAPEUTICS | 25,200 | -4,55 % | Oruka Therapeutics appoints Chris Martin to board of directors | ||
| ARMATA PHARMACEUTICALS | 5,100 | +3,24 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update | LOS ANGELES, Nov. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company... ► Artikel lesen | |
| INNOVIVA | 18,100 | +2,84 % | FDA Approves Innoviva's NUZOLVENCE, First-in-Class Oral Treatment For Gonorrhea | ||
| BRAINSTORM CELL THERAPEUTICS | 0,673 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update | NEW YORK, Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,465 | -0,84 % | SIGA Technologies - Fundamentals intact amid several moving parts | Q325 was a quieter quarter for SIGA following strong Q2 sales, although this was not unexpected given its contract-driven model and inherent revenue lumpiness. No product sales were recorded, with total... ► Artikel lesen | |
| DBV TECHNOLOGIES | 3,260 | +1,09 % | DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 | Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 17,200 | -1,15 % | Syndax Pharmaceuticals, Inc.: Revuforj (revumenib) Named Best New Drug at the Scrip Awards 2025 | ||
| LIQUIDIA | 28,380 | -0,14 % | Arquitos Capital Management's Updates on Liquidia Corporation (LQDA) | ||
| MATINAS BIOPHARMA | 0,800 | -2,45 % | Matinas BioPharma ändert Bedingungen für CEO-Halteprämie bei Kontrollwechsel |
MOLECURE SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,24 % bei einem Aktienkurs von 1,704 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.